Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Journal of Clinical Medicine》 2018-04
Add to Favorite Get Latest Update

Research progress on the role of mTOR and its inhibitors in clinical diagnosis and treatment of breast cancer

WANG Jun-nan;WANG Yi-ran;LI Heng-yu;XU Zheng;School of Basic Medicine,Navy Military Medical University;Department of Oncology,Changhai Hospital,Navy Military Medical University;Department of Thyroid and Breast Surgery,Changhai Hospital,Navy Millitary Medical University;Academic Research Department,Navy Military Medical University;  
Abnormal activation of the PI3K-Akt-mTOR signaling pathway plays an important role in the development of breast cancer.In breast cancer treatment,PI3K-Akt-mTOR signaling pathway is correlated with drug resistance of the endocrine and antihuman epidermal growth factor receptor-2(HER-2)target therapy in breast cancer patients with hormone receptor positive or HER-2 positive.The mTOR is located downstream of the signaling pathway and is closely related to the transcription,translation,proliferation,metabolism,and metastasis of tumor cells.The mTOR inhibitors,which can restore the sensitivity of endocrine therapy,exert anticancer effects by acting on the PI3K-Akt-mTOR signaling pathway through different targets.The present paper reviews the recent progress on mTOR,mTOR inhibitor,and PI3K-Akt-mTOR signaling pathway in breast cancer,and provides a reference for relevant studies and long-term clinical applications.
【CateGory Index】: R737.9
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved